Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival.
Dávila J, González-Calle V, Escalante F, Cerdá S, Puig N, García-Sanz R, Bárez A, Montes C, López R, Alonso JM, Aguilar C, García-Mateo A, Labrador J, Aguilera C, García-Coca A, Hernández R, Mateos MV, Ocio EM. Dávila J, et al. Among authors: ocio em. Br J Haematol. 2022 Jul;198(2):278-287. doi: 10.1111/bjh.18182. Epub 2022 Apr 5. Br J Haematol. 2022. PMID: 35383901
Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.
González-Calle V, Cerdá S, Labrador J, Sobejano E, González-Mena B, Aguilera C, Ocio EM, Vidriales MB, Puig N, Gutiérrez NC, García-Sanz R, Alonso JM, López R, Aguilar C, de Coca AG, Hernández R, Hernández JM, Escalante F, Mateos MV. González-Calle V, et al. Among authors: ocio em. Haematologica. 2017 May;102(5):922-931. doi: 10.3324/haematol.2016.158345. Epub 2017 Jan 25. Haematologica. 2017. PMID: 28126960 Free PMC article.
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
Ocio EM, Motlló C, Rodríguez-Otero P, Martínez-López J, Cejalvo MJ, Martín-Sánchez J, Bladé J, García-Malo MD, Dourdil MV, García-Mateo A, de Arriba F, García-Sanz R, de la Rubia J, Oriol A, Lahuerta JJ, San-Miguel JF, Mateos MV. Ocio EM, et al. Br J Haematol. 2021 Feb;192(3):522-530. doi: 10.1111/bjh.16788. Epub 2020 Jun 5. Br J Haematol. 2021. PMID: 32501528 Free article. Clinical Trial.
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival.
García-Sanz R, Dogliotti I, Zaccaria GM, Ocio EM, Rubio A, Murillo I, Escalante F, Aguilera C, García-Mateo A, García de Coca A, Hernández R, Dávila J, Puig N, García-Álvarez M, Chillón MDC, Alcoceba M, Medina A, González de la Calle V, Sarasquete ME, González M, Gutiérrez NC, Jiménez C. García-Sanz R, et al. Among authors: ocio em. Br J Haematol. 2021 Mar;192(5):843-852. doi: 10.1111/bjh.17028. Epub 2020 Aug 11. Br J Haematol. 2021. PMID: 32780894 Free article.
Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.
González-Calle V, Dávila J, Escalante F, de Coca AG, Aguilera C, López R, Bárez A, Alonso JM, Hernández R, Hernández JM, de la Fuente P, Puig N, Ocio EM, Gutiérrez NC, García-Sanz R, Mateos MV. González-Calle V, et al. Among authors: ocio em. Leukemia. 2016 Oct;30(10):2026-2031. doi: 10.1038/leu.2016.123. Epub 2016 May 2. Leukemia. 2016. PMID: 27133826
Treatment for patients with newly diagnosed multiple myeloma in 2015.
Mateos MV, Ocio EM, Paiva B, Rosiñol L, Martínez-López J, Bladé J, Lahuerta JJ, García-Sanz R, San Miguel JF. Mateos MV, et al. Among authors: ocio em. Blood Rev. 2015 Nov;29(6):387-403. doi: 10.1016/j.blre.2015.06.001. Epub 2015 Jun 12. Blood Rev. 2015. PMID: 26094881 Review.
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.
Puig N, Hernández MT, Rosiñol L, González E, de Arriba F, Oriol A, González-Calle V, Escalante F, de la Rubia J, Gironella M, Ríos R, García-Sánchez R, Arguiñano JM, Alegre A, Martín J, Gutiérrez NC, Calasanz MJ, Martín ML, Couto MDC, Casanova M, Arnao M, Pérez-Persona E, Garzón S, González MS, Martín-Sánchez G, Ocio EM, Coleman M, Encinas C, Vale AM, Teruel AI, Cortés-Rodríguez M, Paiva B, Cedena MT, San-Miguel JF, Lahuerta JJ, Bladé J, Niesvizky R, Mateos MV. Puig N, et al. Among authors: ocio em. Blood Cancer J. 2021 May 21;11(5):101. doi: 10.1038/s41408-021-00490-8. Blood Cancer J. 2021. PMID: 34021118 Free PMC article. Clinical Trial.
Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma.
Fernández de Larrea C, Dávila J, Isola I, Ocio EM, Rosiñol L, García-Sanz R, Cibeira MT, Tovar N, Rovira M, Mateos MV, Miguel JS, Bladé J. Fernández de Larrea C, et al. Among authors: ocio em. Bone Marrow Transplant. 2017 Apr;52(4):567-569. doi: 10.1038/bmt.2016.299. Epub 2016 Nov 21. Bone Marrow Transplant. 2017. PMID: 27869809
Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
López-Corral L, Caballero-Velázquez T, López-Godino O, Rosiñol L, Pérez-Vicente S, Fernandez-Avilés F, Krsnik I, Morillo D, Heras I, Morgades M, Rifon JJ, Sampol A, Iniesta F, Ocio EM, Martin J, Rovira M, Cabero M, Castilla-Llorente C, Ribera JM, Torres-Juan M, Moraleda JM, Martinez C, Vázquez A, Gutierrez G, Caballero D, San Miguel JF, Mateos MV, Pérez-Simón JA. López-Corral L, et al. Among authors: ocio em. Biol Blood Marrow Transplant. 2019 Sep;25(9):1703-1712. doi: 10.1016/j.bbmt.2019.04.026. Epub 2019 May 3. Biol Blood Marrow Transplant. 2019. PMID: 31054983 Free article. Clinical Trial.
140 results